SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending amid discussions around the potential end of the government shutdown and its impact on the market, with some anticipating a "sell the news" event. Community chatter also revolves around the possible release of the Epstein files and their potential market implications, creating uncertainty and volatility. Additionally, economic data releases are in focus, as the White House suggests October numbers may not be released.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending amid renewed scrutiny of President Trump's ties to Jeffrey Epstein, with discussions focusing on newly released emails and reports of Trump's efforts to suppress the release of Epstein files. The community is actively debating the implications of these revelations, with some questioning Trump's motives and others defending him against what they claim are politically motivated attacks. This heightened attention coincides with broader market discussions around the stock's fundamentals and potential for volatility.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending amid anticipation of a potential spot ETF listing on Nasdaq this week, spurring excitement within the community, with some even speculating on significant price increases. Despite general market volatility impacting crypto, the XRP community is focused on the possibility of decoupling from broader market trends and the potential for new investment opportunities through ETFs. Discussions also include perspectives on the regulatory landscape and its impact on XRP's future.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is seeing active discussion around AI valuations and the potential for a tech sector rotation. Community members are debating whether the government shutdown ending will be a "sell the news" event, while also eyeing key technical levels and reacting to intraday price swings. Some traders are closely monitoring potential implications from delayed economic data releases and the unfolding Epstein files.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

CRCL is trending due to a mix of factors, including upcoming earnings and speculation around the IPO lock-up period, which could lead to increased selling pressure; community debates are swirling around its long-term value and potential for a bounce. Despite strong growth in USDC circulation, some express concern about increasing competition and broader market conditions impacting crypto-related stocks.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending due to Shah Capital's renewed push for a company sale, citing frustration with underperformance and unmet potential, sparking community debate about management's competence and potential proxy fights. Shareholders are actively discussing the possibility of a buyout and expressing dissatisfaction with the current leadership, particularly regarding partnership progress and market share. The community's sentiment is further fueled by concerns over dilution and the lack of communication from Novavax regarding Shah Capital's concerns.

Korro Bio, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of a new class of genetic medicines based on editing RNA. The company was founded by Nessan Bermingham, Jean-Francois B. Formela, Joshua Rosenthal, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA.

Korro Bio Inc.

Korro Bio ($KRRO) is trending due to mixed reactions to recent news, including restructuring charges and a paused research program alongside the announcement of a $70M private placement. While some investors are wary of these developments, others see the dip as a buying opportunity, citing the company's substantial cash reserves and RNA editing technology. Community discussions revolve around potential for a bounce and comparisons to other companies in the RNA editing space.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

NBIS is trending due to recent volatility and a mixed market reaction following earnings and news of a potential 25 million share offering. While some investors express concern about dilution and the stock's recent performance, others view it as a buying opportunity, citing strong long-term growth potential in the AI data center sector and recent deals with major companies. Community discussions revolve around identifying the bottom, with some calling for a rebound and others anticipating further declines.

Cisco Systems, Inc. engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Secure, Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products. The company was founded by Sandra Lerner and Leonard Bosack in 1984 and is headquartered in San Jose, CA.

Cisco Systems, Inc.

Cisco ($CSCO) is trending due to a mixed reaction to its earnings report; while Q4 earnings beat expectations, some analysts are concerned with guidance. The community is debating whether the stock's AI infrastructure growth is enough to offset networking headwinds. Discussions also include potential price targets and comparisons to past market bubbles like the dot-com era, with some seeing a buying opportunity while others remain cautious.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

ORCL is trending due to concerns about its debt and spending related to AI infrastructure, leading to a significant pullback from recent highs. Community members are expressing frustration with the stock's persistent decline and lack of management communication, while some speculate about potential accounting issues and the overall sustainability of the AI hype. The stock's performance is being closely watched in the context of broader market trends and the AI sector's future.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>ERNA-101 is designed to activate and regulate the immune system's response to recognize and attack cancer cells.</li><li>The new collaboration comes as the company looks forward to clinical trials for the cell therapy.&nbsp;</li><li>ERNA-101 has shown potential to reprogram immunologically "cold" tumors into "hot" ones, increasing immune cell infiltration and suppressing tumor growth in preclinical studies. &nbsp;</li></ul><blockquote>Shares of Ernexa Therapeutics (ERNA) traded 48% higher on Wednesday afternoon after Cellipont Bioservices announced that it has entered into a collaboration with the company.</blockquote>Cellipont is a cell therapy contract development and manufacturing organization. Its <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/cellipont-bioservices-and-ernexa-therapeutics-enter-cell-therapy-manufacturing-partnership-to-advance-erna-101-toward-clinical-trials-in-ovarian-cancer-302597673.html">partnership</a> with Ernexa will focus on activities to advance Ernexa’s lead cell therapy called ERNA-101 for the treatment of ovarian cancer into clinical manufacturing and trials.<blockquote>"Cellipont brings deep technical capabilities and a shared sense of urgency to help us translate the promise of ERNA-101 into a clinically viable therapy."&nbsp; -Sanjeev Luther, CEO, Ernexa Therapeutics.</blockquote><h2 class="st-heading-2">About The Cell Therapy</h2>ERNA-101 is designed to activate and regulate the immune system's response to recognize and attack cancer cells. According to Cellipont, it provides a scalable, off-the-shelf treatment, without needing patient-specific cell harvesting, provided it is an allogeneic iMSC therapy using stem cells from a healthy donor rather than the patient themselves.ERNA-101 has shown potential to reprogram immunologically "cold" tumors into "hot" ones, increasing immune cell infiltration and suppressing tumor growth in preclinical studies, the company said. The new collaboration comes as the company looks forward to clinical trials for the cell therapy.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ERNA">ERNA stock</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.A Stocktwits user expressed optimism for the stock hitting a new high.<stembedurl>https://stocktwits.com/Roza11/message/634186263</stembedurl>Another, however, sees upcoming dilution.<stembedurl>https://stocktwits.com/Tradebub/message/634144629</stembedurl>ERNA stock is down by 58% this year and by 89% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/bridgebio-shares-second-postive-late-stage-study-results-in-a-week-calcium-disorder-drug-trial-yields-positive-results/cLGZvEeR3DT">BridgeBio Shares Second Positive Late-Stage Study Result In A Week – Calcium Disorder Drug Trial Yields Positive Results</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

ERNA Stock Rallies On Collaboration With Contract Manufacturer To Advance Lead Cell Therapy Into Clinical Trials 

The partnership will focus on activities to advance Ernexa’s lead cell therapy called ERNA-101 for the treatment of ovarian cancer into clinical manufacturing and trials. 

Equity

Cellipont Bioservices and Ernexa Therapeutics Enter Cell Therapy Manufacturing Partnership to Advance ERNA-101 Toward Clinical Trials in Ovarian Cancer

Cellipont Bioservices and Ernexa Therapeutics Enter Cell Therapy Manufacturing Partnership to Advance ERNA-101 Toward Clinical Trials in Ovarian Cancer Cellipont Bioservices and Ernexa Therapeutics...

Shares of Ernexa Therapeutics (ERNA) fell 13% on Tuesday morning after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/06/10/3096816/0/en/Ernexa-Therapeutics-Announces-1-for-15-Reverse-Stock-Split.html">announced</a> a reverse stock split to regain compliance with the $1 minimum bid price required for continued listing on Nasdaq.The reverse stock split will be at a ratio of 1-for-15, effective June 12, 2025, at 12:01 a.m. Eastern Time. The company’s common stock is expected to begin trading on a split-adjusted basis when the market opens on June 12.As a result of the reverse stock split, every 15 shares of the company’s common stock issued and outstanding will be automatically reclassified into one new share of common stock.No fractional shares will be issued in connection with the reverse stock split, and no cash or other consideration will be paid in connection with any fractional shares.As of Tuesday, the company had 110.4 million shares of common stock issued and outstanding, which it anticipates will result in approximately 7.4 million shares of common stock issued and outstanding on a split-adjusted basis.Ernexa also stated that it believes the reverse stock split is a key step in strengthening its financial foundation and maintaining access to the capital markets needed to advance its clinical programs.Ernexa is developing innovative stem cell therapies for the treatment of advanced cancer and autoimmune disease.On Stocktwits, retail sentiment around Ernexa improved from ‘extremely bearish’ to ‘bearish’ territory over the past 24 hours while message volume remained at ‘high’ levels.<figure class="image"><img style="aspect-ratio:629/57;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_10_at_10_35_28_AM_png_969f4ebcc6.webp" alt="ERNA's Sentiment Meter and Message Volume as of 10:30 a.m. ET on June 10, 2025 | Source: Stocktwits" width="629" height="57"><figcaption>ERNA's Sentiment Meter and Message Volume as of 10:30 a.m. ET on June 10, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/ERNA">ERNA stock</a> is down by about 56% this year and by about 91% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/tencent-music-expands-audio-empire-with-over-2-billion-ximalaya-merger/chl7VcFRbzk">Tencent Expands Audio Empire With $2.4B Ximalaya Merger: Retail Turns Optimistic</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Ernexa Stock Drops On 1-For-15 Reverse Stock Split To Regain Nasdaq Compliance: Retail Sentiment Improves But Stays Bearish

As of Tuesday, the company had 110.4 million shares of common stock issued and outstanding, which it anticipates will result in approximately 7.4 million shares on a split-adjusted basis.

Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors

CAMBRIDGE, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) ( Eterna or the Company ), a life science company committed to realizing the potential of mRNA cell...

Eterna Therapeutics Inc. (NASDAQ:ERNA) Short Interest Up 11.7% in January

Eterna Therapeutics Inc. (NASDAQ:ERNA  Get Free Report) saw a large increase in short interest in January. As of January 31st, there was short interest totalling 147,900 shares, an increase of...

Eterna Therapeutics files to sell 18.2M shares for holders

Eterna Therapeutics files to sell 18.2M shares for holders...

Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)

CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) ( Eterna or the Company ), a life science company committed to realizing the potential of mRNA cell...

Ernexa Therapeutics, Inc. engages in the provision of cell engineering therapies. It is involved in the development of mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. The company was founded in 1984 and is headquartered in Cambridge, MA.

Ernexa Therapeutics Inc.

Will NVIDIA ($NVDA) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

ERNA
Eterna Therapeutics Inc

Feed

News

Sentiment

Fundamentals

Info

Latest ERNA News

ERNAEterna Therapeutics Inc